Cannabinoids for Behavioral Problems in Children With ASD

PHASE2CompletedINTERVENTIONAL
Enrollment

150

Participants

Timeline

Start Date

January 31, 2017

Primary Completion Date

October 31, 2018

Study Completion Date

December 31, 2018

Conditions
Autistic Disorder
Interventions
DRUG

Cannabinoids - 99% pure cannabinoids mix

99% pure cannabidiol (CBD) and 99% pure Δ9-tetrahydrocannabinol (THC) in a 20:1 ratio (B.O.L Pharma, Israel), in a 160/8.0 mg per mL (CBD/THC) olive oil-based solution.

DRUG

Placebo

Olive oil and flavors solution.

DRUG

Cannabinoids - whole plant extract

Whole plant extract enriched with cannabidiol (CBD) and Δ9-tetrahydrocannabinol (THC) to achieve 20:1 ratio (B.O.L Pharma, Israel), in a 160/8.0 mg per mL (CBD/THC) olive oil-based solution.

Trial Locations (1)

Unknown

Shaare Zedek Medical Center, Jerusalem

All Listed Sponsors
lead

Shaare Zedek Medical Center

OTHER

NCT02956226 - Cannabinoids for Behavioral Problems in Children With ASD | Biotech Hunter | Biotech Hunter